Nordic Pharma Launches Lacrifill Canalicular Gel for Dry Eye

Nordic Pharma announced the commercial launch of Lacrifill Canalicular Gel, a novel therapy for dry eye in the US. 

Lacrifill is a cross-linked hyaluronic acid derivative and is FDA-cleared to temporarily block tear drainage by the occlusion of the canalicular system. The gel allows patient’s eyes to be bathed in their own natural tears. It is customized for each individual patient and provides a full fill of the canalicular system. Lacrifill is administered through an in-office procedure, which is reimbursed through the existing CPT code (68761), and the results last for 6 months.

“It’s been so exciting to be part of the launch of Lacrifill Canalicular Gel, an interventional dry eye treatment that helps ophthalmologists with cataract, glaucoma and refractive surgeries and all of their dry eye needs. This dry eye therapy is truly changing practice and changing lives,” Chief Commercial Officer of Eye Care US, Jai Parekh, MD, said in a company news release.

Nordic Pharma is attending Kiawah Eye 2024 in Kiawah Island, SC from May 30-June 1 to share information about Lacrifill Canalicular Gel and take orders.

For more information about Lacrifill Canalicular Gel and ordering details, visit lacrifill.com.